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BACKGROUND: Previous studies have suggested a link between metabolic syndrome
(MetS) and prostate cancer (PCa). In the present study, we aimed to assess the
association between MetS and markers of PCa aggressiveness on radical
prostatectomy (RP).
METHODS: All patients consecutively treated for PCa by RP in 6 academic institutions
between August 2013 and July 2016 were included. MetS was defined as at least 3 of 5
components (obesity, elevated blood pressure, diabetes, low high-density lipoprotein
(HDL)-cholesterol, and hypertriglyceridemia). Demographic, biological, and clinical
parameters were prospectively collected, including: age, biopsy results, preoperative
serum prostate-specific antigen, surgical procedure, and pathological data of RP
specimen. Locally advanced disease was defined as a pT-stage ≥3. International
Society of Urological Pathology (ISUP) groups were used for pathological grading.
Qualitative and quantitative variables were compared using chi-square and Wilcoxon
tests; logistic regression analyses assessed the association of MetS and its components
with pathological data. Statistical significance was defined as a P<0.05.
RESULTS: Among 567 men, 249 (44%) had MetS. In a multivariate model including
preoperative prostate-specific antigen, biopsy ISUP-score, clinical T-stage, age, and
ethnicity: we found that MetS was an independent risk factor for positive margins, and
ISUP group ≥4 on the RP specimen (odds ratio [OR] = 1.5; 95% CI: 1.1-2.3; P = 0.035;
OR = 2.0; 95% CI: 1.1-4.0; P = 0.044, respectively). In addition, low HDL-cholesterol
level was associated with locally advanced PCa (OR = 1.6; 95% CI: 1.1-2.4; P = 0.024).
Risks of adverse pathological features increased with the number of MetS components:
having ≥ 4 MetS components was significantly associated with higher risk of ISUP
group ≥ 4 and higher risk of positive margins (OR = 1.9; 95% CI: 1.1-3.3; P = 0.017;
OR = 1.8; 95% CI: 1.1-2.8; P = 0.007, respectively).
CONCLUSION: MetS was an independent predictive factor for higher ISUP group and
positive margins at RP. Low HDL-cholesterol alone, and having 4 and more MetS
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